Cohance Lifesciences Ltd
NSE: COHANCE · Pharmaceuticals · sector
₹463.55NSE close 2026-10-26
Key numbers
Market cap₹17,735 cr
Price₹463.55
52w high / low₹918 / ₹267
P/E166.8xSector median 27.9x
P/B4.5xSector median 2.9x
Book value₹102.2
Dividend yield–Sector median 0.48%
ROE3.8%Sector median 11.7%
ROCE3.3%Sector median 12.3%
OPM13.8%Sector median 14.0%
Debt / equity0.04xSector median 0.16x
EV/EBITDA59.6xSector median 18.6x
Interest cover4.0x
Current ratio2.78x
Sales growth 3y+19.8%Sector median +9.6%
Profit growth 3y-26.6%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹326 cr vs borrowings ₹170 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 4.0x in the last 12 months.
- 94.56% of the promoters' shares are pledged (54.4% of all shares).
- Operating cash flow was below net profit in 1 of the last 4 years (FY22).
- Net loss in 1 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 30% of net profit in the last 12 months.
- Debtor days went from 30 (FY23) to 110 (FY26).
- Dividend paid in 3 of the last 5 financial years.
- Price ₹463.55 on 2026-10-26: -49.5% from the 52-week high, +73.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,334.20 · low ₹282.55
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 258 | 307 | 402 | 549 | 556 | 545 | 619 | 422 |
| EBITDA | 104 | 118 | 74 | 104 | 121 | 90 | 82 | 1 |
| OPM % | 40.4% | 38.3% | 18.3% | 18.9% | 21.8% | 16.6% | 13.3% | 0.3% |
| Other income | 14 | 16 | 11 | 14 | 16 | 6 | -2 | 12 |
| Net profit | 82 | 83 | 42 | 49 | 74 | 37 | 20 | -24 |
| EPS (₹) | 3.23 | 3.26 | 1.65 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
| Revenue YoY | +115.6% | +77.3% | +54.0% | -23.1% | ||||
| Profit YoY | -9.9% | -55.7% | -53.5% | -149.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY21 | FY22 | FY23 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,010 | 1,320 | 1,340 | 1,198 | 2,269 | 2,142 |
| EBITDA | 440 | 579 | 567 | 375 | 398 | 295 |
| Net profit | 362 | 454 | 411 | 268 | 179 | 106 |
| EPS (₹) | 14.23 | 17.83 | 16.16 | 10.52 | 4.69 | 2.78 |
| Revenue growth | +30.8% | +1.5% | -10.7% | +89.4% | +41.2% | |
| Profit growth | +25.2% | -9.4% | -34.9% | -33.1% | -58.5% | |
| Dividend / share (₹) | 1.00 | 2.00 | 2.00 | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +19.8% | – | +41.2% |
| Net profit | -26.6% | – | -58.5% |
| EPS | -35.9% | – | – |
| Share price | – | – (2y) | -48.6% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|
| Shareholders' equity | – | 1,735 | 1,697 | 3,911 |
| Borrowings | – | 69 | 78 | 170 |
| Cash & equivalents | – | 487 | 280 | 326 |
| Total assets | – | 1,966 | 3,032 | 5,730 |
| Fixed assets | – | 584 | 995 | 1,990 |
| Capital work in progress | – | 165 | 255 | 173 |
| Investments | – | 117 | 145 | 262 |
| Receivables | – | 111 | 284 | 681 |
| Inventory | – | 313 | 167 | 562 |
| Payables | – | 65 | 80 | 285 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|
| Cash from operations | 330 | 451 | 288 | 368 |
| Cash from investing | -136 | -195 | -255 | -255 |
| Cash from financing | -156 | -236 | 3 | -165 |
| Capex | 75 | 286 | 156 | 220 |
| Free cash flow | 255 | 165 | 132 | 148 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|
| ROE % | – | 23.7% | 15.8% | 4.6% |
| ROCE % | – | 31.3% | 20.1% | 6.0% |
| Debtor days | – | 30 | 87 | 110 |
| Inventory days | – | 279 | 199 | 310 |
| Payable days | – | 58 | 96 | 157 |
| Cash conversion cycle (days) | – | 251 | 190 | 263 |
| Working capital days | – | 232 | 149 | 185 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 57.48% |
| FIIs | 7.71% |
| DIIs | 18.86% |
| of which Mutual funds | 16.93% |
| of which Insurance | 1.78% |
| Public (non-institutions) | 15.95% |
| Quarter | Mar 2025 | May 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 50.10% | 66.41% | 66.41% | 57.49% | 57.49% | 57.49% | 57.49% | 57.48% |
| Promoter group | % |
|---|---|
| Behryanda Limited | 33.34% |
| Jusmiral Holdings Limited | 24.15% |
| Public holders above 1% | % |
|---|---|
| Jasub Property Holdings LLP | 3.84% |
| SBI MNC Fund | 3.73% |
| ICICI Prudential Healthcare Fund | 3.68% |
| DSP Flexi CAP Fund | 2.90% |
| Jasti Property and Equity Holdings Private Limited | 2.51% |
| Amansa Holdings Private Limited | 2.18% |
| HDFC Trustee Company Limited - HDFC TAX Saverfund | 2.16% |
| SBI Life Insurance Co. Ltd | 1.75% |
| Invesco India Contra Fund | 1.61% |
93,846 shareholders. Pledged: 94.56% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| COHANCE | ₹17,735 cr | 166.8x | 4.5x | 3.8% | 3.3% | 13.8% | +19.8% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-08-06 | Other | Annual General Meeting |
| 2023-12-12 | Other | Annual General Meeting |
| 2022-09-09 | Dividend | Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share |
| 2022-08-11 | Other | Annual General Meeting |
| 2022-05-13 | Dividend | Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share |
| 2022-02-15 | Dividend | Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per Share |
| 2021-08-13 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2021-02-17 | Dividend | Interim Dividend - Re 1 Per Share |
| 2020-09-25 | Bonus | Bonus 1:1 |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | COHANCE |
| BSE code | 543064 |
| ISIN | INE03QK01018 |
| Face value | ₹1.0 |
| Incorporated | 2018-11-06 |
| Website | www.cohance.com |
| Plants (India / abroad) | 13 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.